Following its listing on the London Stock Exchange (LSE) cannabis company Kanabo is set to make its unique vaporiser available to UK patients.
A week after it became the second company to list on the LSE, Israeli firm Kanabo, has announced it will supply its medical-grade inhalation device, VapePod and a line of medicinal cannabis formulations in pods for the UK market.
The company has signed its first distribution agreement with the UK’s biggest cannabis clinic provider, LYPHE Group, which is part of Drug Science’s Project Twenty21.
Through this new agreement, Kanabo’s VapePod medicinal cannabis formula, will be made available to Project Twenty21 patients under LYPHE Group’s brand NOIDECS.
Kanabo seeks to provide an alternative solution to the smoking of medicinal cannabis flowers.
The VapePod will be the first product of its kind, a medical-grade handheld vaporiser with controlled metered dosage, made available to UK cannabis patients with a medical prescription.
It can administer an accurate, measured dose of cannabis extract, which the company hopes will improve patient access and boost trust amongst medical professionals.
The initial formula, which Astral Health will distribute under the name NOIDECS 400T, is based on the Israeli medical cannabis pharmacopoeia as a recommended ratio for pain management.
Kanabo and Astral Health will work closely to make the products available to patients over the coming months.
Avihu Tamir, Kanabo’s CEO commented: “We believe this new product will be revolutionary for medical cannabis patients who need immediate relief of pain, and will replace the smoking of cannabis flowers as a medical delivery method, which is one of Kanabo’s main targets.”
Project Twenty21 provides eligible patients with affordable medical cannabis treatment, monitored by Drug Science and aims to create the UK’s largest body of evidence for the effectiveness and tolerability of medical cannabis.
LYPHE Group announced its partnership with Project Twenty21 in December to bring a range of EU-GMP and equivalent GMP medicines to the UK.
LYPHE Group, which has more than 60 percent of the British patient market, recently entered into a supply partnership with Canadian manufacturer, Northern Green to bring a range of indoor grown flower-based products to the market.
Dean Friday, LYPHE’s CEO added: “We have seen the headlines, and we have witnessed the negative impact of opioids. Pain is not going to go away, so a more natural and caring approach to treating it must find centre stage. Thanks to our partnership with Kanabo we now have a metered dose NOIDECS product that can treat patients across the U.K. that suffer from chronic pain.”
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure
- Science6 months ago
New research suggests alcohol, not cannabis, is the real ‘gateway’ drug